Key points are not available for this paper at this time.
Mebendazole was introduced in 1971 and is not soluble in water or other organic solvents, it is also not absorbed from the intestinal tract in a high-fat context. Both albendazole and mebendazole have a low rate of absorption in the human intestine. These drugs primarily target parasites in the stomach's lumen, and their metabolites are effective against parasites in the stomach's muscles and tissues. For instance, albendazole sulfoxide is the primary metabolite that possesses anthelmintic properties. Metabolites of mebendazole are expelled in the urine. Both drugs negatively affect the function of microtubules in parasites and mammalian cells, this results in the depletion of the parasites' glycogen stores. Current helminth control strategies involve periodic deworming with albendazole or mebendazole. However, concerns about drug resistance and the persistence of high prevalence rates suggest the need for additional strategies, such as improved water, sanitation, and hygiene, and optimized treatment regimens. Albendazole and mebendazole are highly effective against Ascaris lumbricoides, with a single dose of albendazole showing a cure rate of 96% and mebendazole showing a cure rate of 92.3%. Mebendazole's efficacy against hookworms varies, but a recommended dosing regimen improves effectiveness. Mebendazole's effectiveness against Trichuris trichiura depends on the dosing regimen. It is less effective against hymenolepiasis, where praziquantel is preferred. Mebendazole has also been used to treat Giardia lamblia infections. In summary, STH infections are a significant health issue, and albendazole and mebendazole are commonly used drugs for treatment. However, there is a need for additional strategies to address drug resistance and improve treatment efficacy. Mebendazole has potential side effects and should be used with caution, especially during pregnancy.
Mohammed et al. (Fri,) studied this question.